Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Barchart Premier: The most comprehensive method for keeping track of all your investments. FREE 30 Day Trial
Stocks | Futures | Watchlist | More
or

Ironwood Pharmaceuti (IRWD)

Ironwood Pharmaceuti (IRWD)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 931,348
  • Shares Outstanding, K 156,529
  • Annual Sales, $ 442,740 K
  • Annual Income, $ -1,002 M
  • 60-Month Beta 0.57
  • Price/Sales 2.14
  • Price/Cash Flow N/A
  • Price/Book N/A
Trade IRWD with:

Options Overview Details

View History
  • Implied Volatility 124.21% ( +76.16%)
  • Historical Volatility 68.98%
  • IV Percentile 97%
  • IV Rank 47.43%
  • IV High 230.19% on 05/10/24
  • IV Low 28.59% on 01/05/24
  • Put/Call Vol Ratio 0.00
  • Today's Volume 48
  • Volume Avg (30-Day) 129
  • Put/Call OI Ratio 0.16
  • Today's Open Interest 3,791
  • Open Int (30-Day) 12,033

Analyst Rating / Earnings Estimates

Current Rating
See More
Strong Buy
Based on 6 analysts offering recommendations.
Earnings Estimates - Current Qtr 06/30/24
See More
  • Average Estimate 0.17
  • Number of Estimates 4
  • High Estimate 0.20
  • Low Estimate 0.14
  • Prior Year 0.31
  • Growth Rate Est. (year over year) -45.16%

Price Performance

See More
Period Period Low Period High Performance
1-Month
5.85 +1.71%
on 05/24/24
8.45 -29.59%
on 05/03/24
-2.15 (-26.54%)
since 04/24/24
3-Month
5.85 +1.71%
on 05/24/24
15.26 -61.01%
on 02/27/24
-9.12 (-60.52%)
since 02/23/24
52-Week
5.85 +1.71%
on 05/24/24
15.70 -62.10%
on 02/14/24
-4.86 (-44.96%)
since 05/24/23

Most Recent Stories

More News
Ironwood: Q1 Earnings Snapshot

Ironwood: Q1 Earnings Snapshot

IRWD : 5.95 (-1.82%)
Ironwood: Q4 Earnings Snapshot

Ironwood: Q4 Earnings Snapshot

IRWD : 5.95 (-1.82%)
Chart of the Day: Ironwood Pharma - Gastrointestinal Products

The Chart of the Day belongs to the gastrointestinal pharmaceutical products company Ironwood Pharmaceutical (IRWD) I found the stock by using Barchart's powerful screening functions to find stocks...

IRWD : 5.95 (-1.82%)
Ironwood: Q3 Earnings Snapshot

Ironwood: Q3 Earnings Snapshot

IRWD : 5.95 (-1.82%)
Ironwood: Q2 Earnings Snapshot

Ironwood: Q2 Earnings Snapshot

IRWD : 5.95 (-1.82%)
Down 7% in 2023, This Struggling Growth Stock Could Soon Make a Turnaround

Ironwood's plan to purchase a smaller biotech should address some issues that have shareholders concerned.

IRWD : 5.95 (-1.82%)
VECT : 16.85 (unch)
Why Ironwood Pharmaceuticals Stock Bumped Higher Today

Investors indicated approval of the company's upcoming $1 billion asset purchase.

ABBV : 157.06 (-0.76%)
IRWD : 5.95 (-1.82%)
VECT : 16.85 (unch)
Why Shares of VectivBio Holding Are Up Today

A buyout offer by Ironwood Pharmaceuticals lifted the clinical-stage biotech's stock.

VECT : 16.85 (unch)
IRWD : 5.95 (-1.82%)
Ironwood Presents New Data on Potential of Linaclotide for Functional Constipation in Children and Adolescents Ages 6-17 Years-Old at Digestive Disease Week® 2023

Ironwood Pharmaceuticals, Inc. (Nasdaq: IRWD), a GI-focused healthcare company, presented findings during the 2023 Digestive Disease Week ® (DDW) meeting from a Phase III clinical trial on the potential...

IRWD : 5.95 (-1.82%)
Ironwood (IRWD) Q1 Earnings Beat Estimates, Linzess Volume Up

Ironwood (IRWD) reports better-than-expected results, wherein both earnings and revenues beat estimates. The strong momentum of Linzess continues with 10% growth in prescription demand.

AZN : 78.54 (+0.46%)
IRWD : 5.95 (-1.82%)
ABBV : 157.06 (-0.76%)
OCUP : 1.7600 (+2.92%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 88% Sell with a Strongest short term outlook on maintaining the current direction.

The market is in highly oversold territory. Beware of a trend reversal.

See More Share

Business Summary

Ironwood Pharmaceuticals, Inc. focuses on the development and commercialization of treatments primarily addressing gastrointestinal diseases. Linzess was launched in collaboration with Allergan for patients suffering from irritable bowel syndrome (IBS-C; 290 mcg) with constipation or chronic idiopathic...

See More

Key Turning Points

3rd Resistance Point 6.40
2nd Resistance Point 6.27
1st Resistance Point 6.11
Last Price 5.95
1st Support Level 5.82
2nd Support Level 5.69
3rd Support Level 5.53

See More

52-Week High 15.70
Fibonacci 61.8% 11.94
Fibonacci 50% 10.77
Fibonacci 38.2% 9.61
Last Price 5.95
52-Week Low 5.85

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.

Free Barchart Webinar